MDLN Stock Medline (MDLN, $36.59) was a top weekly gainer, with a +5.6% jump
at Tickeron.com
Loading...
Medline (MDLN, $36.59) was one of the top gainers this week, climbing to $36.59 per share. A.I.dvisor analyzed 52 stocks in the Pharmaceuticals: Other Industry over the last week and discovered that of them (4) trended up while of them (5) trended down.
MDLN in upward trend: price expected to rise as it breaks its lower Bollinger Band on September 10, 2026
MDLN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 4 of 4 cases where MDLN's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 23, 2026. You may want to consider a long position or call options on MDLN as a result. In 6 of 8 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.
The Moving Average Convergence Divergence (MACD) for MDLN just turned positive on September 22, 2026. Looking at past instances where MDLN's MACD turned positive, the stock continued to rise in 3 of 5 cases over the following month. The odds of a continued upward trend are 60%.
Following a +1.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDLN advanced for three days, in 33 of 45 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDLN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.659) is normal, around the industry mean (5.011). P/E Ratio (43.875) is within average values for comparable stocks, (163.451). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.456). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.966) is also within normal values, averaging (56.074).
The Tickeron SMR rating for this company is 64 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 71 (best 1 - 100 worst), indicating slightly worse than average price growth. MDLN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDLN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.